Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Active, not recruiting · NCT03674047 · Registry updated 2025-11-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | Other Cancer | Active, not recruiting | Phase 2 | 2025-11-10 | NCT03674047 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Incyte Corporation | 153 |
| Massachusetts General Hospital | 758 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Cancer Center | Duarte | United States | 15 |
| Cleveland Clinic | Cleveland | United States | 558 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| H. Lee Moffitt Cancer Center | Tampa | United States | 13 |
| Huntsman Cancer Institute | Salt Lake City | United States | 107 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Medical College of Wisconsin | Milwaukee | United States | 483 |